An essential receptor for adeno-associated virus infection
Open accessThe DOI matches its Crossref record; 32 of the 33 references it cites were found in a registry or an index.
Abstract
Adeno-associated virus (AAV) vectors are currently the leading candidates for virus-based gene therapies because of their broad tissue tropism, non-pathogenic nature and low immunogenicity. They have been successfully used in clinical trials to treat hereditary diseases such as haemophilia B (ref. 2), and have been approved for treatment of lipoprotein lipase deficiency in Europe. Considerable efforts have been made to engineer AAV variants with novel and biomedically valuable cell tropisms to allow efficacious systemic administration, yet basic aspects of AAV cellular entry are still poorly understood. In particular, the protein receptor(s) required for AAV entry after cell attachment remains unknown. Here we use an unbiased genetic screen to identify proteins essential for AAV serotype 2 (AAV2) infection in a haploid human cell line. The most significantly enriched gene of the screen encodes a previously uncharacterized type I transmembrane protein, KIAA0319L (denoted hereafter as AAV receptor (AAVR)). We characterize AAVR as a protein capable of rapid endocytosis from the plasma membrane and trafficking to the trans-Golgi network. We show that AAVR directly binds to AAV2 particles, and that anti-AAVR antibodies efficiently block AAV2 infection. Moreover, genetic ablation of AAVR renders a wide range of mammalian cell types highly resistant to AAV2 infection. Notably, AAVR serves as a critical host factor for all tested AAV serotypes. The importance of AAVR for in vivo gene delivery is further highlighted by the robust resistance of Aavr(-/-) (also known as Au040320(-/-) and Kiaa0319l(-/-)) mice to AAV infection. Collectively, our data indicate that AAVR is a universal receptor involved in AAV infection.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The peptide insertion at position R588 in R100 sterically prohibits the close proximity between R585 and R588 required for heparan sulfate binding ( Fig. 5 B), suggesting a plausible mechanism for enhanced transit through the heparan sulfate-rich ILM barrier.”
From Design and Characterization of a Novel Intravitreal Dual-Transgene Genetic Medicine for Neovascular Retinopathies (2024) · cites this paper as [45]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing
Benjamini, Y., & Hochberg, Y. (1995) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1995.tb02031.x · Cited by 109,482
Genome engineering using the CRISPR-Cas9 system
Ran, F. A., Hsu, P. D., Wright, J., Agarwala, V., Scott, D. A., & Zhang, F. (2013) · Nature Protocols · doi:10.1038/nprot.2013.143 · Cited by 11,133
In vivo genome editing using Staphylococcus aureus Cas9
Ran, F. A., Cong, L., Yan, W. X., Scott, D. A., Gootenberg, J. S., Kriz, A. J., Zetsche, B., Shalem, O., Wu, X., Makarova, K. S., et al. (2015) · Nature · doi:10.1038/nature14299 · Cited by 2,687
Adenovirus-Associated Virus Vector–Mediated Gene Transfer in Hemophilia B
Nathwani, A. C., Tuddenham, E. G. D., Rangarajan, S., Rosales, C., McIntosh, J., Linch, D. C., Chowdary, P., Riddell, A., Pie, A. J., Harrington, C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1108046 · Cited by 1,864
Maxfield, F. R., & McGraw, T. E. (2004) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1315 · Cited by 1,729
Analysis of AAV Serotypes 1–9 Mediated Gene Expression and Tropism in Mice After Systemic Injection
Zincarelli, C., Soltys, S., Rengo, G., & Rabinowitz, J. E. (2008) · Molecular Therapy · doi:10.1038/mt.2008.76 · Cited by 1,490
Summerford, C., & Samulski, R. J. (1998) · Journal of Virology · doi:10.1128/jvi.72.2.1438-1445.1998 · Cited by 1,406
Ebola virus entry requires the cholesterol transporter Niemann–Pick C1
Carette, J. E., Raaben, M., Wong, A. C., Herbert, A. S., Obernosterer, G., Mulherkar, N., Kuehne, A. I., Kranzusch, P. J., Griffin, A. M., Ruthel, G., et al. (2011) · Nature · doi:10.1038/nature10348 · Cited by 1,303
Self-citationMannose 6-phosphate receptors: new twists in the tale
Ghosh, P., Dahms, N. M., & Kornfeld, S. (2003) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1050 · Cited by 1,086
A Versatile Viral System for Expression and Depletion of Proteins in Mammalian Cells
Campeau, E., Ruhl, V. E., Rodier, F., Smith, C. L., Rahmberg, B. L., Fuss, J. O., Campisi, J., Yaswen, P., Cooper, P. K., & Kaufman, P. D. (2009) · PLoS ONE · doi:10.1371/journal.pone.0006529 · Cited by 964
Cited by
Items 101–200 of 524
Qu, Y., Liu, Y., Noor, A. F., Tran, J., & Li, R. (2019) · Neural Regeneration Research · doi:10.4103/1673-5374.250570 · Cited by 56
“The structure of AAV involves one single-stranded DNA with an inverted terminal repeat as the viral genome and one protein capsid (Cassinotti et al., 1988; Lentz et al., 2012; Pillay et al., 2016).”
Loregger, A., Raaben, M., Nieuwenhuis, J., Tan, J. M. E., Jae, L. T., van den Hengel, L. G., Hendrix, S., van den Berg, M., Scheij, S., Song, J.-Y., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-14811-1 · Cited by 51
Self-citationSerotype survey of AAV gene delivery via subconjunctival injection in mice
Song, L., Llanga, T., Conatser, L. M., Zaric, V., Gilger, B. C., & Hirsch, M. L. (2018) · Gene Therapy · doi:10.1038/s41434-018-0035-6 · Cited by 50
“S4, EGFR, 37/67 kDa Lam R, AAVR, and sialic acid were also present in the conjunctiva in mice, while the 37/67 kDa Lam R, AAVR, HSPG as well as sialic acid were also detected in mouse retina.”
InfluentialFuture of rAAV Gene Therapy: Platform for RNAi, Gene Editing, and Beyond
Valdmanis, P. N., & Kay, M. A. (2017) · Human Gene Therapy · doi:10.1089/hum.2016.171 · Cited by 58
“Notable examples include the identification of the KIAA0319L type I transmembrane (AAVR) receptor for AAV entry, 121 the heparan sulfate proteoglycan identified for AAV2 attachment, 122 and the N-linked terminal galactosyl residue binding speci-ficity for AAV9.”
Adipose Tissue: An Emerging Target for Adeno-associated Viral Vectors
Bates, R., Huang, W., & Cao, L. (2020) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2020.09.009 · Cited by 54
“Recent studies have shed new light on molecular mechanisms of engagement between the AAV receptor and AAV2 and other serotypes.(25,28) However, the mechanisms of AAV attachment and entry into adipocytes are unknown.”
BackgroundWang, J.-H., Zhan, W., Gallagher, T. L., & Gao, G. (2024) · Molecular Therapy · doi:10.1016/j.ymthe.2024.10.017 · Cited by 53
Editing the Central Nervous System Through CRISPR/Cas9 Systems
Cota-Coronado, A., Díaz-Martínez, N. F., Padilla‐Camberos, E., & Diaz-Martinez, N. E. (2019) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2019.00110 · Cited by 58
“Interestingly, vectors such as AAV1, AAV5, and AAV9 do not have affinity for heparan sulfate proteoglycans (HSPGs); therefore, they can distribute after a single injection into the brain (Pillay et al., 2016).”
BackgroundWagner, H. J., Weber, W., & Fussenegger, M. (2021) · Advanced Science · doi:10.1002/advs.202004018 · Cited by 54
Emerging technologies to study glial cells
Hirbec, H., Déglon, N., Foo, L. C., Goshen, I., Grutzendler, J., Hangen, E., Kreisel, T., Linck, N., Muffat, J., Regio, S., et al. (2020) · Glia · doi:10.1002/glia.23780 · Cited by 47
Cryo-electron Microscopy of Adeno-associated Virus
Stagg, S. M., Yoshioka, C., Davulcu, O., & Chapman, M. S. (2022) · Chemical Reviews · doi:10.1021/acs.chemrev.1c00936 · Cited by 50
Self-citationHan, Z., Luo, N., Ma, W., Liu, X., Cai, Y., Kou, J., Wang, J., Li, L., Peng, S., Xu, Z., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-39554-7 · Cited by 53
A role for glycolipid biosynthesis in severe fever with thrombocytopenia syndrome virus entry
Drake, M. J., Brennan, B., Briley, K., Bart, S. M., Sherman, E. A., Szemiel, A. M., Madeleine, M., Bushman, F. D., & Bates, P. F. (2017) · PLoS Pathogens · doi:10.1371/journal.ppat.1006316 · Cited by 49
Callaway, H., Welsch, K., Weichert, W. S., Allison, A. B., Hafenstein, S. L., Huang, K., Iketani, S., & Parrish, C. R. (2018) · Journal of Virology · doi:10.1128/jvi.00460-18 · Cited by 46
Hartmann, J., Münch, R. C., Freiling, R.-T., Schneider, I. C., Dreier, B., Samukange, W. T., Koch, J., Seeger, M. A., Plückthun, A., & Buchholz, C. J. (2018) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2018.07.001 · Cited by 54
“In this respect, it will be important to determine if attachment of the DARPin to its receptor is sufficient or if secondary receptors like the recently identified AAVR are required in addition for cell entry of receptor re-targeted AAV vectors.(38) Interestingly, DARPin 2K19, which performed best on AAV, does not exh…”
BackgroundMuraine, L., Bensalah, M., Dhiab, J., Córdova, G., Arandel, L., Marhic, A., Chapart, M., Vasseur, S., Benkhelifa‐Ziyyat, S., Bigot, A., et al. (2019) · Human Gene Therapy · doi:10.1089/hum.2019.173 · Cited by 54
“A new cellular AAV receptor (also named KIAA0319L) has also recently been described as essential for AAV cell entry following attachment.(39,40) In our study, none of the vectors were able to induce the expression of LacZ in interstitial cells (fibroblasts and inflammatory cells) (Fig.”
BackgroundLe, D. T., Radukic, M. T., & Müller, K. M. (2019) · Scientific Reports · doi:10.1038/s41598-019-54928-y · Cited by 43
Positron emission tomography imaging of novel AAV capsids maps rapid brain accumulation
Seo, J. W., Ingham, E. S., Mahakian, L. M., Tumbale, S. K., Wu, B., Aghevlian, S., Shams, S., Baikoghli, M., Jain, P., Ding, X., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-15818-4 · Cited by 47
Cabanes‐Creus, M., Westhaus, A., Navarro, R. G., Baltazar, G., Zhu, E., Amaya, A. K., Liao, S. H. Y., Scott, S., Sallard, E., Dilworth, K. L., et al. (2020) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2020.05.004 · Cited by 45
AAV-8 and AAV-9 Vectors Cooperate with Serum Proteins Differently Than AAV-1 and AAV-6
Denard, J., Rouillon, J., Leger, T., Garcia, C., Lambert, M. P., Griffith, G., Jenny, C., Camadro, J.-M., Garcia, L., & Svinartchouk, F. (2018) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2018.08.001 · Cited by 44
“Importantly, during the next step of transduction, cellular entry, different AAV serotypes use different domains of the universal AAV cellular entry receptor (adeno-associated virus receptor [AAVR]).(32,33) It would not be surprising if serum components interacting with rAAV-1 and rAAV-6 from one side, and rAAV-8 and…”
BackgroundStructural and cellular biology of adeno-associated virus attachment and entry
Zengel, J. R., & Carette, J. E. (2020) · Advances in virus research · doi:10.1016/bs.aivir.2020.01.002 · Cited by 54
Self-citationDelivering AAV to the Central Nervous and Sensory Systems
Peters, C. W., Maguire, C. A., & Hanlon, K. S. (2021) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2021.03.004 · Cited by 45
The molecular mechanisms underlying acrosome biogenesis elucidated by gene-manipulated mice†
Xiong, W., Shen, C., & Wang, Z. (2021) · Biology of Reproduction · doi:10.1093/biolre/ioab117 · Cited by 47
“It could be possible that AU040320 is somehow necessary for the proper formation of PAVs or in the recruitment of cargo proteins by adaptor proteins AP-1 and/or AP-2 that would in turn be required in downstream events leading to the acrosomal delivery and fusion.”
BackgroundXu, G., Zhang, R., Li, H., Yin, K., Ma, X., & Lou, Z. (2022) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2022.05.009 · Cited by 45
“Recent study elucidated that AAVR interacting VR-I also participates in AAV9 galactose binding and might have been selected during evolution to ensure the virus internalization;(15) this is in line with the role of AAVR facilitating intracellular trafficking of the virus.(9,28)”
BackgroundMontizaan, D., Bartucci, R., Reker‐Smit, C., de Weerd, S., Åberg, C., Guryev, V., Spierings, D. C. J., & Salvati, A. L. (2024) · Nature Nanotechnology · doi:10.1038/s41565-024-01629-x · Cited by 45
An engineered AAV targeting integrin alpha V beta 6 presents improved myotropism across species
Hong, A. V., Suel, L., Petat, E., Dubois, A., Brun, P., Guerchet, N., Veron, P., Poupiot, J., & Richard, I. (2024) · Nature Communications · doi:10.1038/s41467-024-52002-4 · Cited by 48
“S2H) and test the viral transduction ef fi - ciency in comparison to 293_WT. Similar to other engineered capsids with peptide-inserted VR8 17,42 , AAV9rh74_4um9 and _5ff0 reduced the AAV entry by 65.37% and 74.73%, reduced the transgene activity by 94.10% and 96.90% with the absence of AAVR (Fig.”
BackgroundInfluentialSłyk, Ż., Stachowiak, N., & Małecki, M. (2024) · Biomedicines · doi:10.3390/biomedicines12071523 · Cited by 44
Using rAAV2-retro in rhesus macaques: Promise and caveats for circuit manipulation
Cushnie, A. K., El-Nahal, H. G., Bohlen, M. O., May, P. J., Basso, M. A., Grimaldi, P., Wang, M. Z., de Velasco, E. M. F., Sommer, M. A., & Heilbronner, S. R. (2020) · Journal of Neuroscience Methods · doi:10.1016/j.jneumeth.2020.108859 · Cited by 41
“Pillay and colleagues (2016) recently identified a receptor – AAV receptor (AAVR) – that is essential for infection by all AAV serotypes (Pillay et al., 2016).”
BackgroundAdeno-associated virus infection and its impact in human health: an overview
Sant’Anna, T. B. F., & Araujo, N. M. (2022) · Virology Journal · doi:10.1186/s12985-022-01900-4 · Cited by 40
Katz, M. G., Fargnoli, A. S., Weber, T., Hajjar, R. J., & Bridges, C. R. (2017) · Human Gene Therapy Clinical Development · doi:10.1089/humc.2017.070 · Cited by 42
“Recently, a putative universal AAV receptor has been described, but its function in AAV transduction remains to be elucidated.(3) After receptor binding, the virions are efficiently endocytosed via the CLIC/ GEEC pathway,(4) although a less efficient, dynamindependent pathway may also play a role in AAV infection.”
BackgroundTMEFF1 is a neuron-specific restriction factor for herpes simplex virus
Dai, Y., Idorn, M., Serrero, M. C., Pan, X., Thomsen, E. A., Narita, R., Maimaitili, M., Qian, X., Iversen, M. B., Reinert, L. S., et al. (2024) · Nature · doi:10.1038/s41586-024-07670-z · Cited by 38
AAV microdystrophin gene replacement therapy for Duchenne muscular dystrophy: progress and prospects
Chwalenia, K., Feng, V.-Y., Hemmer, N., Friedrichsen, H. J., Vorobieva, I., Wood, M. J. A., & Roberts, T. C. (2025) · Gene Therapy · doi:10.1038/s41434-025-00561-6 · Cited by 44
“Co-receptors including integrins, laminins, and growth factor receptors also contribute to AAV internalization [84, 85].”
Engineering AAV receptor footprints for gene therapy
Madigan, V. J., & Asokan, A. (2016) · Current Opinion in Virology · doi:10.1016/j.coviro.2016.05.001 · Cited by 38
Zhang, P., Moreno, R., Lambert, P. F., & DiMaio, D. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1917748117 · Cited by 37
Meyer‐Berg, H., Zhou-Yang, L., de Lucas, M. P., Zambrano, A., Hyde, S. C., & Gill, D. R. (2020) · Stem Cell Research & Therapy · doi:10.1186/s13287-020-01950-x · Cited by 41
Genetic Modification of the Lung Directed Toward Treatment of Human Disease
Sondhi, D., Stiles, K. M., De, B. P., & Crystal, R. G. (2017) · Human Gene Therapy · doi:10.1089/hum.2016.152 · Cited by 36
Xie, Q., Spear, J. M., Noble, A. J., Sousa, D. R., Meyer, N. L., Davulcu, O., Zhang, F., Linhardt, R. J., Stagg, S. M., & Chapman, M. S. (2017) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2017.02.004 · Cited by 37
“Furthermore, at high multiplicity of infection, overexpression of KIAA0319L can overcome the inhibitory effect of a heparan synthesis cell knockout.(49) The results of this research add to the emerging picture that the glycan binding site can tolerate lower specificity interactions than once anticipated.”
Self-citationViral mechanisms for docking and delivering at nuclear pore complexes
Flatt, J. W., & Greber, U. F. (2017) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2017.05.008 · Cited by 39
Luteijn, R. D., van Diemen, F. R., Blomen, V. A., Boer, I. G. J., Sadasivam, S. M., Kuppevelt, T. H. V., Drexler, I., Brummelkamp, T. R., Lebbink, R. J., & Wiertz, E. J. H. J. (2019) · Journal of Virology · doi:10.1128/jvi.02160-18 · Cited by 38
Zhang, Z., Zhu, Z., Chen, W., Cai, Z., Xu, B., Tan, Z., Wu, A., Ge, X., Guo, X., Tan, Z., et al. (2018) · Bioinformatics · doi:10.1093/bioinformatics/bty694 · Cited by 38
Hardwiring tissue-specific AAV transduction in mice through engineered receptor expression
Zengel, J. R., Wang, Y. X., Seo, J. W., Ning, K., Hamilton, J. N., Wu, B., Raie, M. N., Holbrook, C., Su, S., Clements, D. R., et al. (2023) · Nature Methods · doi:10.1038/s41592-023-01896-x · Cited by 38
Self-citationTechnologies for Proteome-Wide Discovery of Extracellular Host-Pathogen Interactions
Martinez-Martín, N. (2017) · Journal of Immunology Research · doi:10.1155/2017/2197615 · Cited by 36
“More recently, Pillay and colleagues applied the haploid cell screening approach to the identification of host factors essential for the adeno-associated virus (AAV) serotype 2 infection, one of the leading vectors for virus-based genes therapies [49] .”
InfluentialAdeno‐associated virus‐based Alzheimer's disease mouse models and potential new therapeutic avenues
Ittner, L. M., Klugmann, M., & Ke, Y. D. (2019) · British Journal of Pharmacology · doi:10.1111/bph.14637 · Cited by 39
“While all AAVs infect cells via a universal cellular AAV receptor (AAVR), they differ in their distinctive molecular interaction with AAVR in a serotype‐dependent manner as well as specificity for other receptors and co‐receptors (Pillay et al., 2016; Pillay et al., 2017).”
BackgroundYuan, Z., Li, B., Gu, W., Luozhong, S., Li, R., & Jiang, S. (2022) · Journal of the American Chemical Society · doi:10.1021/jacs.2c09484 · Cited by 38
Kremer, L. P. M., Cerrizuela, S., Dehler, S., Stiehl, T., Weinmann, J., Abendroth, H., Kleber, S., Laure, A., Andari, J. E., Anders, S., et al. (2021) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2021.07.001 · Cited by 35
Liver directed adeno‐associated viral vectors to treat metabolic disease
Chuecos, M. A., & Lagor, W. R. (2023) · Journal of Inherited Metabolic Disease · doi:10.1002/jimd.12637 · Cited by 36
“33 37 utilize a recently identified common receptor called AAV receptor (AAVR) (KIAA0319L) 38 to enter cells.”
BackgroundHigh-Throughput Dissection of AAV–Host Interactions: The Fast and the Curious
Herrmann, A.-K., & Grimm, D. (2018) · Journal of Molecular Biology · doi:10.1016/j.jmb.2018.05.022 · Cited by 38
Emmanuel, S. N., Mietzsch, M., Tseng, Y.-S., Smith, J. K., & Agbandje‐McKenna, M. (2021) · Viral Immunology · doi:10.1089/vim.2020.0022 · Cited by 33
“The AAVs utilize various glycan and protein receptors (5,32,56,65,82, 96,100,121,128,132) for cell attachment and entry, and thus differ in tissue tropism (42,102,119).”
BackgroundOncolytic H-1 parvovirus binds to sialic acid on laminins for cell attachment and entry
Kulkarni, A. S., Ferreira, T., Bretscher, C., Grewenig, A., El‐Andaloussi, N., Bonifati, S., Marttila, T., Palissot, V., Hossain, J. A., Azuaje, F. J., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-24034-7 · Cited by 36
Zhang, L., Rossi, A., Lange, L., Meumann, N., Koitzsch, U., Christie, K. A., Nesbit, M. A., Moore, C. B. T., Hacker, U. T., Morgan, M. A., et al. (2019) · Human Gene Therapy · doi:10.1089/hum.2019.027 · Cited by 34
“16,43 Recently, two groups mapped the AAVR binding site for AAV2 to the spike region adjacent to the threefold axis of symmetry.”
Self-citationGene therapy research for kidney diseases
Davis, L., & Park, F. (2019) · Physiological Genomics · doi:10.1152/physiolgenomics.00052.2019 · Cited by 38
“With these types of new findings, our understanding about the biology of AAV may not be as fully understood as anticipated, especially with the recent identification of cellular factors, such as the AAV receptor (77) and the assemblyactivating protein (86), that can play a pivotal role in controlling AAV binding and e…”
BackgroundIntramuscular Delivery of Gene Therapy for Targeting the Nervous System
Tosolini, A. P., & Sleigh, J. N. (2020) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2020.00129 · Cited by 32
Structural basis of receptor usage by the engineered capsid AAV-PHP.eB
Jang, S., Shen, H. K., Ding, X., Miles, T. F., & Gradinaru, V. (2022) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2022.07.011 · Cited by 40
“eB interact with the PKD2 domain of AAVR, and the 7-mer orientation predicts the AAVR binding strength AAVR is a direct receptor for multiple AAVs, including AAV9, and is essential for efficient cell infection.(16,17) After determining the”
BackgroundIn vivo engineering of murine T cells using the evolved adeno-associated virus variant Ark313
Nyberg, W. A., Wang, C. H., Ark, J., Liu, C., Clouden, S., Qualls, A., Caryotakis, S. E., Wells, E., Simon, K. E., Garza, C., et al. (2025) · Immunity · doi:10.1016/j.immuni.2025.01.009 · Cited by 34
Viral vectors for gene delivery to the inner ear
Maguire, C. A., & Corey, D. P. (2020) · Hearing Research · doi:10.1016/j.heares.2020.107927 · Cited by 34
Yin, S., Ma, L., Shao, T., Zhang, M., Guan, Y., Wang, L., Hu, Y., Chen, X., Han, H., Shen, N., et al. (2020) · Science China Life Sciences · doi:10.1007/s11427-020-1744-6 · Cited by 39
Capsid-mediated control of adeno-associated viral transcription determines host range
Loeb, E. J., Havlik, P. L., Elmore, Z. C., Rosales, A., Fergione, S. M., Gonzalez, T. J., Smith, T. J., Benkert, A. R., Fiflis, D. N., & Asokan, A. (2024) · Cell Reports · doi:10.1016/j.celrep.2024.113902 · Cited by 35
Genome-scale identification of cellular pathways required for cell surface recognition
Sharma, S., Scott, J. B., Couch, A. C. M., Yusa, K., & Wright, G. J. (2018) · Genome Research · doi:10.1101/gr.231183.117 · Cited by 34
“It is known that cells treated with com- pounds that increase lysosomal pH cause IGF2R to accumulate in endosomes with a consequent loss from the cell surface, providing an explanation for why genes required for endosomal function and trafficking were also enriched (Reaves and Banting 1994).”
BackgroundEngineering challenges and translational opportunities in emerging gene delivery platforms
Ma, Y., Dong, S., Wu, A., Jeong, S. D., Lee, A. S., Jiang, W., & Kim, B. Y. S. (2026) · Nature Biomedical Engineering · doi:10.1038/s41551-026-01643-5 · Cited by 49
“For example, AAV2 binds heparan sulfate proteoglycans, AAV5 targets sialic acids and AAV9 binds galactose 79,80 , and for most cap-sids, including many engineered variants, also relies on the multi-capsid AAV receptor (KIAA0319L) for efficient entry 81 .”
Silveria, M., Large, E. E., Zane, G. M., White, T., & Chapman, M. S. (2020) · Viruses · doi:10.3390/v12111326 · Cited by 32
“Essential in the infection pathway of all AAVs, except the AAV4 clade [12], is the host protein AAVR [13], a cell receptor that likely plays a role in AAV’s tissue tropism [14].”
BackgroundSelf-citationKo, C., Su, J., Festag, J., Bester, R., Kosinska, A. D., & Protzer, U. (2021) · Antiviral Research · doi:10.1016/j.antiviral.2021.105140 · Cited by 34
AAV genome modification for efficient AAV production
Asaad, W., Volos, P., Maksimov, D. O., Khavina, E. M., Deviatkin, A. A., Mityaeva, O. N., & Volchkov, P. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e15071 · Cited by 33
Sano, H., Kobayashi, K., Yoshioka, N., Takebayashi, H., & Nambu, A. (2020) · Journal of Neuroscience Methods · doi:10.1016/j.jneumeth.2020.108887 · Cited by 29
Wang, W., Liu, J., Yang, M., Qiu, R., Li, Y., Bian, S., Hao, B., & Lei, B. (2021) · Human Gene Therapy · doi:10.1089/hum.2020.328 · Cited by 30
“24 In contrast, a physical membrane namely the inner limiting layer may further reduce the transduction of the vector in the target retinal tissue, resulting in decrease of the efficiency.”
Dudek, A. M., & Porteus, M. H. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.660302 · Cited by 32
“DNA virus induced caspase-3 has also been shown to cleave cGAS, MAVS, and IRF3 to prevent overproduction of inflammatory cytokines (91), demonstrating that there is cross-talk between DNA sensing pathways and suggesting that aspects of the cellular response can be post-transcriptionally regulated.”
BackgroundSutter, S. O., Lkharrazi, A., Schraner, E. M., Michaelsen, K., Meier, A. F., Marx, J., Vogt, B., Büning, H., & Fraefel, C. (2022) · PLoS Pathogens · doi:10.1371/journal.ppat.1010187 · Cited by 34
Shay, T. F., Jang, S., Brittain, T. J., Chen, X., Walker, B., Tebbutt, C., Fan, Y., Wolfe, D. A., Arokiaraj, C. M., Sullivan, E. E., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-52149-0 · Cited by 30
“Pre-screen optimizations were performed on slides of HEK293 cells and cells overexpressing mouse LY6A and human AAVR (KIAA0319L), TGFBR2, and EGFR.”
Advances in high-throughput methods for the identification of virus receptors
Barrass, S. V., & Butcher, S. J. (2019) · Medical Microbiology and Immunology · doi:10.1007/s00430-019-00653-2 · Cited by 31
“Adeno-associated virus (AAV) serotype 2 KIAA0319L Random insertional mutagenesis in Haploid cells [56]”
BackgroundMethodA comparison of AAV-vector production methods for gene therapy and preclinical assessment
Davidsson, M., Negrini, M., Hauser, S., Svanbergsson, A., Lockowandt, M., Tomasello, G., Manfredsson, F. P., & Heuer, A. (2020) · Scientific Reports · doi:10.1038/s41598-020-78521-w · Cited by 31
Cabanes‐Creus, M., Navarro, R. G., Liao, S. H. Y., Baltazar, G., Drouyer, M., Zhu, E., Scott, S., Luong, C., Wilson, L. O. W., Alexander, I. E., et al. (2021) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2021.04.010 · Cited by 29
“This is not in contradiction to published data, given that only functional tests, specifically luciferase expression assays, were performed.(17) However, our data are more consistent with a model where AAVR plays a similar role in AAV transduction to the Golgi calcium transport pump SPCA1,(28) which has recently been…”
ResultHörner, M., Jerez‐Longres, C., Hudek, A., Hook, S., Yousefi, O. S., Schamel, W. W. A., Hörner, C., Zurbriggen, M. D., Ye, H., Wagner, H. J., et al. (2021) · Science Advances · doi:10.1126/sciadv.abf0797 · Cited by 30
Ning, K., Zou, W., Xu, P., Cheng, F., Zhang, E. Y., Zhang-Chen, A., Kleiboeker, S. B., & Qiu, J. (2023) · Science Advances · doi:10.1126/sciadv.ade0869 · Cited by 31
“Resultsshownare cell surface expression of AXL in the indicated cell types. protein, which is higher than the binding affinity between most viruses with their cognate receptors ( 44 , 48 ).”
AAV2-Mediated Transduction of the Mouse Retina After Optic Nerve Injury
Nickells, R. W., Schmitt, H. M., Maes, M. E., & Schlamp, C. L. (2017) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.17-22634 · Cited by 27
Polarized AAVR expression determines infectivity by AAV gene therapy vectors
Hamilton, B. A., Li, X., Pezzulo, A. A., Alaiwa, M. H. A., & Zabner, J. (2019) · Gene Therapy · doi:10.1038/s41434-019-0078-3 · Cited by 29
Ring finger protein 121 is a potent regulator of adeno-associated viral genome transcription
Madigan, V. J., Yuziuk, J. A., Chiarella, A. M., Tyson, T. O., Meganck, R. M., Elmore, Z. C., Tse, L. V., Hathaway, N. A., & Asokan, A. (2019) · PLoS Pathogens · doi:10.1371/journal.ppat.1007988 · Cited by 28
Zdechlik, A. C., He, Y., Aird, E. J., Gordon, W. R., & Schmidt, D. (2019) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.9b00790 · Cited by 31
López-Astacio, R. A., Adu, O. F., Lee, H., Hafenstein, S. L., & Parrish, C. R. (2023) · Journal of Virology · doi:10.1128/jvi.00161-23 · Cited by 30
Adeno-associated virus (AAV) capsid engineering in liver-directed gene therapy
Rodríguez-Márquez, E., Meumann, N., & Büning, H. (2020) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2021.1865303 · Cited by 30
“This process depends on host factors such as adeno-associated virus receptor 1 (AAVR1) or GPR108 [16,35], and requires endosomal acidification and presumably endosomal enzyme activity to induce the above-mentioned VP1 and VP2 extrusion through pores located at the five-fold symmetry axis of the capsid [36].”
BackgroundThe emerging role of viral vectors as vehicles for DMD gene editing
Maggio, I., Chen, X., & Gonçalves, M. A. F. V. (2016) · Genome Medicine · doi:10.1186/s13073-016-0316-x · Cited by 27
“The recently discovered pan-AAV receptor AAVR [68] is likely to have an important role in this research; for instance, by shedding light on rAAV transduction profiles in different cell types, including immune-related cells.”
Madigan, V. J., Berry, G. E., Tyson, T. O., Nardone-White, D. T., Ark, J., Elmore, Z. C., Murlidharan, G., Vincent, H. A., & Asokan, A. (2020) · Journal of Virology · doi:10.1128/jvi.01604-20 · Cited by 25
“As noted above, the ATP2C1 gene was listed as a hit in a haploid genetic screen for essential AAV host factors (9).”
BackgroundLiu, Y. B., Xu, B., Chen, Y., Yuan, X., Liu, J., Liu, T., Du, G. Z., Jiang, W., Yang, Y., Zhu, Y. F., et al. (2021) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2021.05.015 · Cited by 26
“Furthermore, AAVR was verified to be essential for cellular entry of most natural AAV serotypes, except for AAV4.(23) EC71 and”
BackgroundMethodInfluentialAdeno‐associated virus serotype 2 capsid variants for improved liver‐directed gene therapy
Meumann, N., Cabanes‐Creus, M., Ertelt, M., Navarro, R. G., Lucifora, J., Yuan, Q., Nien‐Huber, K., Abdelrahman, A. M., Vu, X., Zhang, L. N., et al. (2023) · Hepatology · doi:10.1002/hep.32733 · Cited by 27
“Furthermore, AAV receptor (AAVR) and G protein–coupled receptor (GPR) 108 escort AAV's intracellular processing,[7,8] eventually leading to uncoating, i.”
BackgroundAncestral Library Identifies Conserved Reprogrammable Liver Motif on AAV Capsid
Zinn, E. M., Unzu, C., Schmit, P. F., Turunen, H., Zabaleta, N., Sanmiguel, J. C., Fieldsend, A., Bhatt, U., Diop, C. T., Merkel, E., et al. (2021) · Cell Reports Medicine · doi:10.1016/j.xcrm.2022.100803 · Cited by 30
“Interestingly, liver-off vectors require AAVR for cell transduction, as both AAV2 and AAV8 group AAVs are dependent on AAVR for transduction based in vitro and in vivo.(78,79) In Adachi et al.”
BackgroundGene Therapy for Hemophilia: Progress to Date
Chapin, J. C., & Monahan, P. E. (2017) · BioDrugs · doi:10.1007/s40259-017-0255-0 · Cited by 26
“In addition, a pan-AAV receptor (AAVR) was recently identified as a universal element for AAV internalization of many different AAV serotypes by host cells [87].”
BackgroundApproaches to identify extracellular receptor–ligand interactions
Wood, L., & Wright, G. J. (2018) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2018.10.002 · Cited by 27
Ellsworth, J. L., Gingras, J., Smith, L. J., Rubin, H., Seabrook, T. A., Patel, K., Zapata, N., Olivieri, K., O’Callaghan, M., Chlipala, E., et al. (2019) · PLOS ONE · doi:10.1371/journal.pone.0225582 · Cited by 25
The Influence of Murine Genetic Background in Adeno-Associated Virus Transduction of the Mouse Brain
He, T., Itano, M. S., Earley, L. F., Hall, N. E., Riddick, N., Samulski, R. J., & Li, C. (2019) · Human Gene Therapy Clinical Development · doi:10.1089/humc.2019.030 · Cited by 25
Impact of liver fibrosis on AAV-mediated gene transfer to mouse hepatocytes
Ferriero, R., Bruno, G., Padula, A., Pisano, S., Boffa, I., Gargaro, M., Imperatore, T., Battipaglia, M., Vivenzio, S., Perna, C., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-57382-9 · Cited by 26
Retina-directed gene therapy: Achievements and remaining challenges
Biber, J., Gandor, C. L. A., Bećirović, E., & Michalakis, S. (2025) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2025.108862 · Cited by 25
Receptor Switching in Newly Evolved Adeno-associated Viruses
Havlik, L. P., Das, A., Mietzsch, M., Oh, D. K., Ark, J., McKENNA, R. V., Agbandje‐McKenna, M., & Asokan, A. (2021) · Journal of Virology · doi:10.1128/jvi.00587-21 · Cited by 26
“Mapping of structure-function correlates for natural AAVs has greatly improved our understanding of their infectious pathways and tissue tropism.”
BackgroundInfluentialZhang, C., Zhou, X., Yao, T., Tian, Z., & Zhou, D. (2018) · Biotechnology Journal · doi:10.1002/biot.201700374 · Cited by 25
Hartmann, J., Thalheimer, F. B., Höpfner, F., Kerzel, T., Khodosevich, K., García‐González, D., Monyer, H., Diester, I., Büning, H., Carette, J. E., et al. (2019) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2019.07.004 · Cited by 27
“To assess the role of AAVR in the entry of GluA4-AAV, we made use of the cell line A549, which had been genetically engineered to destroy AAVR expression.(24)We equipped the parental and the knockout (ko) line with GluA4 and verified the presence of GluA4 and absence of AAVR by flow cytometry or western blot analysis…”
Self-citationAAV8 virions hijack serum proteins to increase hepatocyte binding for transduction enhancement
Pei, X., He, T., Hall, N. E., Gerber, D., Samulski, R. J., & Li, C. (2018) · Virology · doi:10.1016/j.virol.2018.02.007 · Cited by 23
Nuclease-Mediated Gene Therapies for Inherited Metabolic Diseases of the Liver.
Te, B., Anglin, C. M., Bridges, P. H., & Cottle, R. N. (2017) · PubMed Central · Cited by 33
Nuclear entry and egress of parvoviruses
Mattola, S., Aho, V., Bustamante-Jaramillo, L. F., Pizzioli, E., Kann, M., & Vihinen‐Ranta, M. (2022) · Molecular Microbiology · doi:10.1111/mmi.14974 · Cited by 26
“Recently, the AAV receptor (AAVR; KIAA0319L) was identified as an essential receptor for cell internalization and trafficking of different AAVs (Meyer & Chapman, 2022; Pillay et al., 2016).”
BackgroundChemical approaches to probe and engineer AAV vectors
Pham, Q. T., Glicksman, J., & Chatterjee, A. (2024) · Nanoscale · doi:10.1039/d4nr01300j · Cited by 26
“14 15 – 17 This secondary interaction initiates diverse internalization pathways, resulting in tra ffi cking to endosomal and Golgi compartments.”
BackgroundWang, J., & Zhang, L. (2021) · Microbes and Infection · doi:10.1016/j.micinf.2021.104829 · Cited by 29
Eliminating mesothelioma by AAV-vectored, PD1-based vaccination in the tumor microenvironment
Tan, Z., Chiu, M. S., Yan, C. W., Man, K., & Chen, Z. (2021) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2021.01.010 · Cited by 22
Guidi, L., Holloway, Z. G., Arnoult, C., Ray, P. F., Monaco, A. P., Molnár, Z., & Velayos‐Baeza, A. (2018) · Scientific Reports · doi:10.1038/s41598-018-28666-6 · Cited by 26
Rodríguez-Estévez, L., Asokan, P., & Borrás, T. (2019) · Gene Therapy · doi:10.1038/s41434-019-0105-4 · Cited by 25
Tracking Adeno-Associated Virus Capsid Evolution by High-Throughput Sequencing
de Alencastro, G., Pekrun, K., Valdmanis, P., Tiffany, M., Xu, J., & Kay, M. A. (2020) · Human Gene Therapy · doi:10.1089/hum.2019.339 · Cited by 21
Metadata
- Authors
- Pillay, S., Meyer, N. L., Puschnik, A. S., Davulcu, O., Diep, J., Ishikawa, Y., Jae, L. T., Wosen, J. E., Nagamine, C. M., Chapman, M. S., & Carette, J. E.
- Affiliations
- Stanford Medicine (US)
- Oregon Health & Science University (US)
- The Netherlands Cancer Institute (NL)
- Corresponding author
- Chapman, M. S.
- Carette, J. E.
- ORCID
- Venue
- Nature
- Published
- 2016-01-27
- Volume
- 530
- Issue
- 7588
- Pages
- 108-112
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC4962915
- OpenAlex
- W2266837556
- Cited by
- 532
- References
- 33
- Citations by year
- 2026: 58 · 2025: 51 · 2024: 63 · 2023: 60 · 2022: 36 · 2021: 47 · 2020: 57 · 2019: 50 · 2018: 43 · 2017: 37 · 2016: 28
- FWCI
- 43.04
- Type
- journal article
- Language
- en
- Update notices
- erratum (2016-09-28)
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- National Institutes of Health (5u19ai109662-05)
- National Institute of General Medical Sciences (R01GM066875)
- National Institute of Allergy and Infectious Diseases (DP2AI104557, U19-AI109662)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Health Sciences › Medicine › Epidemiology › Virology and Viral Diseases
- Keywords
- adeno-associated virus, AAV receptor, AAV2, viral entry, host factors, endocytosis, AAV serotypes, gene therapy vectors, viral gene delivery
- MeSH terms
- Dependovirus, Animals, Antibodies, Cell Line, Endocytosis, Female, Humans, Male, Parvoviridae Infections, Receptors, Cell Surface, Receptors, Virus, Genetic Therapy, Gene Deletion, trans-Golgi Network, Mice, Virus Internalization, Viral Tropism, Host Specificity
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.